MedTrace Logo

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

NCT02730819 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-10-20

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to gather information on the effectiveness and tolerability of a novel composition of existing U.S. Food and Drug Administration (FDA) approved topical medications for the treatment of moderate to severe melasma.

Conditions

  • Melasma

Interventions

DRUG

Illuminate Cream

Topical compound applied daily

Sponsors & Collaborators

Principal Investigators

  • Jason C Sluzevich, M.D. · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-15
Primary Completion
2016-12-30
Completion
2016-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02730819 on ClinicalTrials.gov